EMERYVILLE, Calif.--(BUSINESS WIRE)--Octant, Inc., a synthetic biology drug discovery company designing small molecule, multi-target drug leads for multifactorial diseases announced that it has raised ...
Octant, a company backed by Andreessen Horowitz just now unveiling itself publicly to the world, is using the tools of synthetic biology to buck the latest trends in drug discovery. As the ...
EMERYVILLE, Calif.--(BUSINESS WIRE)--Octant, Inc. (“Octant” or the “Company”), a next-generation, data-driven therapeutics company developing programmable biology and chemistry to build precision ...
“We have been working with Mark for over a year as a Board Member and are thrilled to share that he’s now working with us day-to-day,” said Sri Kosuri, CEO of Octant. “Mark’s unique experience and ...
Octant doubles its initial investment in Zymergen’s Automation Technology to significantly increase the scale and throughput of its drug discovery platform EMERYVILLE, Calif., July 14, 2022 (GLOBE ...
Octant Bio set out on a journey to show that the convergence of synthetic biology, chemistry, and computational techniques could lead to new drugs for patients. That destination is still distant, but ...
Octant Inc. has received a $4.9 million grant from the Gates Foundation to support a new therapeutics program focused on human papillomavirus (HPV)-related cancers. The initiative will develop ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results